Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia

Author(s): Goldberg JM, Scully RE, Sallan SE, Lipshultz SE

Abstract

In 1977, a 5-year-old girl diagnosed with acute lymphoblastic leukemia was treated on Dana-Farber Cancer Institute Childhood Acute Lymphoblastic Leukemia Protocol 77-01, receiving a cumulative doxorubicin dose of 465 mg/m2, cranial radiation, and other drugs. After being in continuous complete remission for 34 months, she developed heart failure and was treated with digoxin and furosemide. At 16 years of age, she was diagnosed and treated for dilated cardiomyopathy. Over the years, she continued to have bouts of heart failure, which became less responsive to treatment. At 36 years of age, she received a heart transplant. Six months later, she stopped taking her medications and suffered a sudden cardiac death.

Similar Articles

Cardiotoxicity and cardioprotection in childhood cancer

Author(s): Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, et al.

Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death

Author(s): Kobayashi S, Volden P, Timm D, Mao K, Xu X, et al.

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience

Author(s): Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al.

Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer

Author(s): Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, et al.

Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging

Author(s): Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al.

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

Author(s): Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE

Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child

Author(s): Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, et al.

Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy

Author(s): Kurihara C, Nishimura T, Nawata K, Kinoshita O, Hisagi M, et al.

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

Author(s): Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al.

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure

Author(s): Palazzuoli A, Gallotta M, Quatrini I, Nuti R

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management

Author(s): Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

Author(s): Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, et al.